Sarah G. Hymowitz

What is she best known for?

The fields of study she is best known for:

• Enzyme
• Amino acid
• Apoptosis

Her primary scientific interests are in Cell biology, Receptor, Apoptosis, Biochemistry and Cancer cell. As a part of the same scientific study, Sarah G. Hymowitz usually deals with the Cell biology, concentrating on Programmed cell death and frequently concerns with Osteoprotegerin. Her work in the fields of Ectodomain overlaps with other areas such as Morphogen.

Her Apoptosis study integrates concerns from other disciplines, such as Molecular biology and Cell culture. Biochemistry is frequently linked to Interleukin 17 in her study. Her work deals with themes such as Antibody, Antigen, Function and Mechanism of action, which intersect with Cancer cell.

Her most cited work include:

• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
• Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease (1009 citations)
• Therapeutic antibody targeting of individual Notch receptors (590 citations)

What are the main themes of her work throughout her whole career to date?

Her primary areas of investigation include Cell biology, Receptor, Biochemistry, Crystal structure and Stereochemistry. Her research integrates issues of Protein structure and Apoptosis, Programmed cell death in her study of Cell biology. Her Apoptosis study combines topics from a wide range of disciplines, such as Cancer cell, Cell culture and Pharmacology.

Her Cell culture research focuses on In vivo and how it connects with Cancer. The concepts of her Receptor study are interwoven with issues in Tumor necrosis factor alpha, Molecular biology, Antibody, B-cell activating factor and Binding site. Biochemistry connects with themes related to Interleukin 17 in her study.

She most often published in these fields:

• Cell biology (32.76%)
• Receptor (26.72%)
• Biochemistry (22.41%)

What were the highlights of her more recent work (between 2012-2020)?

• Kinase (7.76%)
• Cell biology (32.76%)
• Cancer research (8.62%)

In recent papers she was focusing on the following fields of study:

Sarah G. Hymowitz spends much of her time researching Kinase, Cell biology, Cancer research, Protein kinase domain and Phosphorylation. Her study with Kinase involves better knowledge in Biochemistry. Her Cell biology research integrates issues from Receptor and Tnf superfamily.

Her work on Tumor necrosis factor receptor as part of general Receptor research is often related to Promiscuity, thus linking different fields of science. Her Cancer research is multidisciplinary, incorporating elements of Bcl-xL, Leukemia and Apoptosis. Her work is dedicated to discovering how In vivo, Platelet are connected with Pharmacology and other disciplines.

Between 2012 and 2020, her most popular works were:

• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
• Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 (173 citations)
• Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity (154 citations)

In her most recent research, the most cited papers focused on:

• Enzyme
• Amino acid
• Cancer

Sarah G. Hymowitz focuses on Cancer research, Platelet, KRAS, Kinase activity and Point mutation. Her studies deal with areas such as Leukemia and Antitumor activity as well as Platelet. Her Leukemia research includes elements of Cancer, Navitoclax, In vivo and Pharmacology.

Her Navitoclax study introduces a deeper knowledge of Apoptosis. Her biological study spans a wide range of topics, including Signal transduction, MAPK/ERK pathway, Phosphorylation and Protein kinase domain. Her Kinase activity research is multidisciplinary, incorporating perspectives in Proto-Oncogene Proteins B-raf and Conserved sequence.